Mutational signatures and processes in hepatobiliary cancers

Research output: Contribution to journal › Review › Research › peer-review

Standard

Mutational signatures and processes in hepatobiliary cancers. / Zhuravleva, Ekaterina; O'Rourke, Colm J; Andersen, Jesper B.

In: Nature Reviews. Gastroenterology & Hepatology, Vol. 19, 2022, p. 367-382.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Zhuravleva, E, O'Rourke, CJ & Andersen, JB 2022, 'Mutational signatures and processes in hepatobiliary cancers', Nature Reviews. Gastroenterology & Hepatology, vol. 19, pp. 367-382. https://doi.org/10.1038/s41575-022-00587-w

APA

Zhuravleva, E., O'Rourke, C. J., & Andersen, J. B. (2022). Mutational signatures and processes in hepatobiliary cancers. Nature Reviews. Gastroenterology & Hepatology, 19, 367-382. https://doi.org/10.1038/s41575-022-00587-w

Vancouver

Zhuravleva E, O'Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nature Reviews. Gastroenterology & Hepatology. 2022;19:367-382. https://doi.org/10.1038/s41575-022-00587-w

Author

Zhuravleva, Ekaterina ; O'Rourke, Colm J ; Andersen, Jesper B. / Mutational signatures and processes in hepatobiliary cancers. In: Nature Reviews. Gastroenterology & Hepatology. 2022 ; Vol. 19. pp. 367-382.

Bibtex

@article{253f901940c24bba9120cdc9e70e1513,
title = "Mutational signatures and processes in hepatobiliary cancers",
abstract = "The evolutionary history of hepatobiliary cancers is embedded in their genomes. By analysing their catalogue of somatic mutations and the DNA sequence context in which they occur, it is possible to infer the mechanisms underpinning tumorigenesis. These mutational signatures reflect the exogenous and endogenous origins of genetic damage as well as the capacity of hepatobiliary cells to repair and replicate DNA. Genomic analysis of thousands of patients with hepatobiliary cancers has highlighted the diversity of mutagenic processes active in these malignancies, highlighting a prominent source of the inter-cancer-type, inter-patient, intertumour and intratumoural heterogeneity that is observed clinically. However, a substantial proportion of mutational signatures detected in hepatocellular carcinoma and biliary tract cancer remain of unknown cause, emphasizing the important contribution of processes yet to be identified. Exploiting mutational signatures to retrospectively understand hepatobiliary carcinogenesis could advance preventative management of these aggressive tumours as well as potentially predict treatment response and guide the development of therapies targeting tumour evolution.",
author = "Ekaterina Zhuravleva and O'Rourke, {Colm J} and Andersen, {Jesper B}",
note = "{\textcopyright} 2022. Springer Nature Limited.",
year = "2022",
doi = "10.1038/s41575-022-00587-w",
language = "English",
volume = "19",
pages = "367--382",
journal = "Nature Reviews. Gastroenterology & Hepatology",
issn = "1759-5045",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Mutational signatures and processes in hepatobiliary cancers

AU - Zhuravleva, Ekaterina

AU - O'Rourke, Colm J

AU - Andersen, Jesper B

N1 - © 2022. Springer Nature Limited.

PY - 2022

Y1 - 2022

N2 - The evolutionary history of hepatobiliary cancers is embedded in their genomes. By analysing their catalogue of somatic mutations and the DNA sequence context in which they occur, it is possible to infer the mechanisms underpinning tumorigenesis. These mutational signatures reflect the exogenous and endogenous origins of genetic damage as well as the capacity of hepatobiliary cells to repair and replicate DNA. Genomic analysis of thousands of patients with hepatobiliary cancers has highlighted the diversity of mutagenic processes active in these malignancies, highlighting a prominent source of the inter-cancer-type, inter-patient, intertumour and intratumoural heterogeneity that is observed clinically. However, a substantial proportion of mutational signatures detected in hepatocellular carcinoma and biliary tract cancer remain of unknown cause, emphasizing the important contribution of processes yet to be identified. Exploiting mutational signatures to retrospectively understand hepatobiliary carcinogenesis could advance preventative management of these aggressive tumours as well as potentially predict treatment response and guide the development of therapies targeting tumour evolution.

AB - The evolutionary history of hepatobiliary cancers is embedded in their genomes. By analysing their catalogue of somatic mutations and the DNA sequence context in which they occur, it is possible to infer the mechanisms underpinning tumorigenesis. These mutational signatures reflect the exogenous and endogenous origins of genetic damage as well as the capacity of hepatobiliary cells to repair and replicate DNA. Genomic analysis of thousands of patients with hepatobiliary cancers has highlighted the diversity of mutagenic processes active in these malignancies, highlighting a prominent source of the inter-cancer-type, inter-patient, intertumour and intratumoural heterogeneity that is observed clinically. However, a substantial proportion of mutational signatures detected in hepatocellular carcinoma and biliary tract cancer remain of unknown cause, emphasizing the important contribution of processes yet to be identified. Exploiting mutational signatures to retrospectively understand hepatobiliary carcinogenesis could advance preventative management of these aggressive tumours as well as potentially predict treatment response and guide the development of therapies targeting tumour evolution.

U2 - 10.1038/s41575-022-00587-w

DO - 10.1038/s41575-022-00587-w

M3 - Review

C2 - 35273358

VL - 19

SP - 367

EP - 382

JO - Nature Reviews. Gastroenterology & Hepatology

JF - Nature Reviews. Gastroenterology & Hepatology

SN - 1759-5045

ER -

ID: 300770558